The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Tóm tắt
The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, additional trials of relevance for SGLT2i have been published. This update re-evaluates the clinical recommendations for using SGLTi and their indirect comparison with existing evidence on GLP-1RA as compared to the standard of care to reduce cardiorenal morbidity and mortality. We updated our existing search and screening of the literature from September 2021 to April 2023 for randomized controlled trials of SGLT2i and GLP-1RA with placebo control. We conducted risk of bias assessment, data extraction and updated our meta-analysis of studies with similar interventions and components. The certainty of the evidence was determined using GRADE. Evidence from three new trials and additional results from an updated existing trial on SGLT2i met our inclusion criteria after an updated search. Across all the included studies, the total sample size was 151,023 adults, with 90,943 in SGLT2i trials and 60,080 in GLP-1 RA trials. The mean age ranged from 59.9 to 68.4 years. Compared with standard care, the use of SGLT2i and GLP-1 RA showed significant reductions in the outcomes of cardiovascular (CV) mortality (14% & 13%), any-cause mortality (12% & 12%), major adverse CV events (MACE) (11% & 14%), heart failure (HF) hospitalization (30% & 9%), CV death or HF hospitalization (23% & 11%), and kidney composite outcome (32% & 22%). In participants with T2D, both classes demonstrated significant cardiorenal protection. But, only GLP-1RA showed a reduction in non-fatal stroke (16%) and only SGLT2i showed a reduction in HF hospitalization (30%) in this population of people living with T2D. This updated and comprehensive meta-analysis substantiates and strengthens the clinical recommendations of the CCS cardiorenal guidelines.
Tài liệu tham khảo
Mancini GBJ et al. 2022 Canadian Cardiovascular Society Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults Can J Cardiol, 2022. 38(8): p. 1153–1167.
Ali MU, et al. The effectiveness of sodium-glucose cotransporter 2 inhibitors and glucagon-like Peptide-1 receptor agonists on Cardiorenal outcomes: systematic review and Meta-analysis. Can J Cardiol. 2022;38(8):1201–10.
Group E-KC et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med, 2022.
Solomon SD, et al. Dapagliflozin in Heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–98.
Filippatos G, et al. Empagliflozin for Heart failure with preserved left ventricular ejection Fraction with and without diabetes. Circulation. 2022;146(9):676–86.
Voors AA, et al. Renal effects of empagliflozin in patients hospitalized for acute heart failure: from the EMPULSE trial. Eur J Heart Fail. 2022;24(10):1844–52.
Higgins JP et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 343: p. d5928.
Schünemann H, Brożek J, Guyatt G, Oxman A. In: Group TGW, editor. GRADE handbook for grading quality of evidence and strength of recommendations. Editor: Updated; 2013.
DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.
Assink M. W.C.J.M., Fitting three-level meta-analytic models in R: a step-by-step tutorial. Quant Methods Psychol, 2016. 12(3).
Pastor D. On the Multilevel Nature of Meta-Analysis: a Tutorial, Comparison of Software Programs, and discussion of Analytic choices. Multivar Behav Res. 2018;53(1):74–89.
Deeks JJ, Higgins JPT, Altman DG. Analysing data and undertaking meta-analyses, in Cochrane Handbook for Systematic Reviews of Interventions, C.H.f.S.R.o. Interventions Editor, 2019: p. 241–284.
Page MH. J.S., JAC, Assessing risk of bias in a non-randomized study, in Cochrane Handbook for Systematic Reviews of Interventions. 2019. p. 621–641.
Viechtbauer W. Conducting Meta-analyses in R with the meta for Package. J Stat Softw, 2010. 36(3).
Moher D, et al. Preferred reporting items for systematic reviews and Meta-analyses: the PRISMA Statement. PLoS Med. 2009;6(7):e1000097.
Bhatt DL, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. New England journal of medicine; 2020.
Neal B, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
Perkovic V, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
Heerspink HJL, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–46.
McMurray JJV, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008.
Wiviott SD, et al. Dapagliflozin and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
Zinman B, et al. Empagliflozin, Cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
Packer M, et al. Cardiovascular and renal outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413–24.
Bhatt DL, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–39.
Cannon CP, et al. Cardiovascular outcomes with Ertugliflozin in Type 2 diabetes. N Engl J Med. 2020;383(15):1425–35.
Anker SD, et al. Empagliflozin in Heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–61.
Pfeffer MA, et al. Lixisenatide in patients with type 2 diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373(23):2247–57.
Holman RR, et al. Effects of once-weekly Exenatide on Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39.
Leiter LA, et al. Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. Cardiovasc Diabetol. 2019;18(1):73.
Marso SP, et al. Liraglutide and Cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22.
Husain M, et al. Oral Semaglutide and Cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381(9):841–51.
Gerstein HC, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121–30.
Hernandez AF, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (harmony outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392(10157):1519–29.
Gerstein HC, et al. Cardiovascular and renal outcomes with Efpeglenatide in Type 2 diabetes. New England journal of medicine; 2021.
Novo Nordisk A. S. A research study to see how semaglutide works compared to placebo in people with type 2 diabetes and chronic kidney disease (FLOW). ClinicalTrials. gov. Bethesda, MD, National Library of Medicine 2019 Last Accessed 06/12/2023].
Novo Nordisk. A Research Study to See How Semaglutide Works Compared to Placebo in People With Type 2 Diabetes and Chronic Kidney Disease (FLOW). 2023 [cited 2023; Available from: https://clinicaltrials.gov/study/NCT03819153#more-information.
Novo Nordisk. Semaglutide Effects on Heart Disease and Stroke in Patients With Overweight or Obesity (SELECT). 2023 [cited 2023; Available from: https://clinicaltrials.gov/study/NCT03574597.
Novo Nordisk. Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity (STEP-HFpEF). 2023 [cited 2023; Available from: https://clinicaltrials.gov/study/NCT04788511.